Comparative Pharmacology
Head-to-head clinical analysis: GYNOREST versus NORETHINDRONE AND ETHINYL ESTRADIOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GYNOREST versus NORETHINDRONE AND ETHINYL ESTRADIOL.
GYNOREST vs NORETHINDRONE AND ETHINYL ESTRADIOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gynorest (dydrogesterone) is a synthetic progestogen that binds to the progesterone receptor with high selectivity, inducing conformational changes that promote transcription of progesterone-responsive genes. It has no androgenic, estrogenic, or corticosteroid activity, and does not inhibit ovulation.
Combination estrogen-progestin contraceptive. Suppresses gonadotropin release (FSH, LH) via negative feedback on hypothalamic-pituitary axis, inhibiting ovulation. Thickens cervical mucus to inhibit sperm penetration. Alters endometrium to reduce implantation likelihood.
100 mg orally twice daily for 5-10 days or 300 mg orally once daily for 6-12 days.
One tablet (norethindrone 1 mg / ethinyl estradiol 0.035 mg) orally once daily for 21 days, followed by 7 days of placebo or no tablets.
None Documented
None Documented
Terminal elimination half-life is approximately 16-20 hours; supports twice-daily dosing for maintenance of therapeutic levels.
Norethindrone: 6-8 hours (terminal); Ethinyl estradiol: 13-27 hours (terminal, mean ~17 hours). Half-life supports once-daily dosing for contraceptive efficacy.
Renal: 50-80% as metabolites; Fecal: 20-50% as metabolites; Biliary excretion contributes to fecal elimination.
Norethindrone: ~50% renal (as metabolites), ~50% fecal (biliary). Ethinyl estradiol: ~40% renal, ~60% fecal (primarily as glucuronide conjugates).
Category C
Category D/X
Progestin
Progestin